Estimating need and coverage for five priority assistive products: a systematic review of global population-based research

Jamie Danemayer ,1 Dorothy Boggs ,2 Vinicius Delgado Ramos ,3 Emma Smith,4 Ariana Kular,5 William Bhot,1 Felipe Ramos-Barajas ,1, Sarah Polack,2 Cathy Holloway1

ABSTRACT

Introduction To improve access to assistive products (APs) globally, data must be available to inform evidence-based decision-making, policy development and evaluation, and market-shaping interventions.

Methods This systematic review was undertaken to identify studies presenting population-based estimates of need and coverage for five APs (hearing aids, limb prostheses, wheelchairs, glasses and personal digital assistants) grouped by four functional domains (hearing, mobility, vision and cognition).

Results Data including 656 AP access indicators were extracted from 207 studies, most of which (n=199, 96%) were cross-sectional, either collecting primary (n=167) or using secondary (n=32) data. There was considerable heterogeneity in assessment approaches used and how AP indicators were reported; over half (n=110) used a combination of clinical and self-reported assessment data. Of 35 studies reporting AP use out of all people with functional difficulty in the corresponding functional domains, the proportions ranged from 4.5% to 47.0% for hearing aids, from 0.9% to 17.6% for mobility devices, and from 0.1% to 86.6% for near and distance glasses. Studies reporting AP need indicators demonstrated >60% unmet need for each of the five APs in most settings.

Conclusion Variation in definitions of indicators of AP access have likely led to overestimates/underestimates of need and coverage, particularly, where the relationship between functioning difficulty and the need for an AP is complex. This review demonstrates high unmet need for APs globally, due in part to disparate data across this sector, and emphasises the need to standardise AP data collection and reporting strategies to provide a comparable evidence base to improve access to APs.

INTRODUCTION

Assistive technology (AT) includes assistive products (APs) and related services that can improve health and well-being, enable increased independence and foster participation for people with functional difficulties, including older adults and people with

Key questions

What is already known?

► Access to assistive technology (AT) is limited globally, especially in low/middle-income countries (LMICs), largely due to sparse, disparate data on assistive products (APs).

► Currently, there exists no dedicated repository of population-based AP research.

► As a result, many governments lack coherent information about unmet AP need, which can hinder development of evidence-based programmes and policies to address this gap.

What are the new findings?

► The finding of high unmet need (>60%) for each of the five APs emphasises the need to secure political prioritisation and funding to expand access to AT globally.

► Vision is proportionately overrepresented in the literature, with 76% of studies reporting all or in part on glasses. ‘AP use’ was reported 195 times overall (30% of all 656 indicators), making it the most commonly reported AP indicator from this dataset.

► Discrepancies in how key terms related to AP access were defined likely led to overestimates/underestimates of need.

What do the new findings imply?

► Synthesising disparate evidence and comparing across country contexts and functional domains provided a strong base to advocate for increasing access to APs, while identifying underrepresented regions, populations and APs.

► The evidence basis in LMICs is particularly sparse, demonstrating that knowledge gaps are widest, where AP access is the most limited.

► The development of a global minimum dataset on AP research is needed, as well as future research that disaggregates domain-specific and region-specific AP access by additional variables (eg, gender, income and education).
impairments or chronic health conditions. This paper uses the umbrella term ‘functional difficulty’ (FD) to refer to all of these groups.

The WHO estimates 2.4 billion people globally have FD and over 1 billion need APs and related services. This need is expected to rise as populations age, which forecasts an increase in years lived with FD. Furthermore, in some low/middle-income countries (LMICs), higher prevalence of chronic and infectious disease and injury-related morbidity, coupled with a shortage of trained care workers, results in higher overall rates of FD and associated increased demand on healthcare, rehabilitation and AT service delivery systems. The SARS-CoV-2 (COVID-19) pandemic has also resulted in increased FD prevalence due to disruptions of health/rehabilitation services and its direct impact on health and functioning. This includes ‘long COVID–19’, where symptoms decreasing functional abilities persist, the full impact of which is yet to be fully realised.

Despite AT’s critical relevance to all 17 sustainable development goals, the sector has not received equitable attention on the international agenda. Data on AP need are essential to support decision-makers to secure political prioritisation, identify causes of delivery system bottlenecks, and implement interventions to address population-level AT access. Information on this access is lacking, including estimates of use, unmet needs, and met needs, due in part to the complexity of assessing individuals for AP need. Further, due to disparate patterns of data collection, analysis, and reporting, it’s often unclear what data are available and impactful data may go unused. An essential next step is, therefore, to centralise and collate available data indicating AP access and synthesise learnings across APs and functional domains to inform the sector overall.

Assistive product lists (APLs) (PAPs) are used to focus and coordinate efforts to expand AP access. Further specifying a list of priority assistive products (PAPs) at the national level is encouraged in specific countries to ensure the list is contextual and based on their unique needs. The WHO Global Cooperation on Assistive Technology’s priority assistive product list presents a global list of 50 priority APs. Of these, ATScale, a Global Partnership for Assistive Technology, selected five priority APs corresponding to four functional domains: hearing aids (hearing), limb prostheses and wheelchairs (mobility), glasses (vision) and personal digital assistants (PDAs) (cognition).

Aims

To contribute to a global effort to increase the AT evidence base, we conducted a systematic review of studies, which generated population-based AP access indicators for the five priority ATScale APs. This review aims to (1) characterise existing population-level research producing AP access indicators and (2) present and synthesise indicators globally to support scaling up AT provision.

This review builds on the findings of an initial scoping review, commissioned by the WHO and published separately, which primarily focused on the strengths, limitations and most effective contexts for different methods used for estimating AP supply and demand at market level in AT research. Results from these methodologies are explored in this systematic review.

METHODS

The systematic search was conducted in March 2020 and included peer-reviewed articles and grey literature with findings on APs. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement was followed throughout review.

AP access indicators defined

Population-level AP access indicators are variably used and defined in the literature. Table 1 shows the definitions used for the purposes of this review, developed by

| Table 1 AP access indicators definitions and calculations |
|-----------------------------------------------|
| AP access indicator | Working definition | Equation |
|---------------------|--------------------|----------|
| Need                | The proportion of a defined population who could benefit from using an appropriate AP, based on an AP assessment approach, including those already using the AP | Population who could benefit from an AP/defined population |
| Has AP              | The proportion of a defined population who have an AP (obtained through purchase, loan, rent, donation or by other means) | Population who have APs/defined population |
| Use                 | The proportion of a defined population who use an AP | Population who use APs/defined population |
| Met need (population with full coverage) | The proportion of a defined population who need and use appropriate APs | Population who need and use appropriate APs/defined population |
| Undermet need (population with partial coverage) | The proportion of a defined population who need and use APs that are insufficient to maximise functioning | Population who use insufficient APs/defined population |
| Unmet need (population with no coverage) | The proportion of a defined population who need and do not use any APs | Population who need and do not use appropriate APs/defined population |
| Coverage            | The proportion of a defined population who need and use an AP | Population who need and use APs/defined population |

AP, assistive product.
drawing on authors’ expertise and relevant background literature (table 1). These terms are referred to as ‘indicators’ throughout this paper.

**Search strategy**

Fifteen databases were searched for empirical and grey literature using a set search string specifying (1) a synonym for AP or the name of the actual AP, (2) an indicator and (3) a synonym for FD in the study’s title/abstract (online supplemental appendices 1 and 2). Studies were exported to the Rayyan QCRI web application¹³ to remove duplicates and screen abstracts.

**Eligibility criteria**

Our search included studies published between 2000 and 2020, written originally in English, French, Portuguese, or Spanish, or providing a translation. Studies were eligible for inclusion if they met the following criteria during full text review:

- At least a portion of study data is collected since 1 January 2000.
- The study generated at least one indicator (table 1) for one of the five specified priority APs.¹⁰
- The study was a primary or secondary analysis of a representative, population-based sample.

**Review**

After removing duplicates, all titles and abstracts were initially screened for any mention of AT or FD. Remaining abstracts were then reviewed by two authors, according to eligibility criteria.⁹ In addition, eligible systematic reviews were cross-referenced; any relevant citations missing from our searches were added. All full texts were then reviewed by two authors. Conflicts at all stages were settled by a third reviewer.

**Data extraction and analysis**

Data were extracted from full texts and entered into a data portal designed by authors to standardise data extraction for the following: study setting, population, design, assessment methodologies, impairment definitions used, and indicators, including numerator and denominator values (online supplemental appendix 3).

Indicators were included if (1) they were directly reported in the results of studies, meaning they aligned with our terms and definitions (table 1) or (2) they were indirectly reported, meaning it was possible to calculate them using clearly defined data provided in the articles (demonstrated in online supplemental appendix 4).

Given substantial variation in how indicators are presented and reported, not all results were directly comparable and a meta-analysis could not be conducted. Where studies present pooled estimates from previously published results (eg, reviews), the unique pooled indicator was extracted. To facilitate comparison across studies where possible, indicator denominators are denoted in our results tables with the following labels:

- Total population: the broader regional or national population from which the study sample was drawn.

This denominator is larger than the number of participants when study results are only presented as extrapolations.

- Total in analysis: all participants included in the study’s analysis. This may be smaller than the number of total participants reported in a study, as some participants may not complete all components of the assessments.

- Total with FD: all study participants assessed to have the relevant impairment (eg, vision impairment) or functioning difficulty (eg, difficulty seeing). Some studies only include individuals with impairment/FD as participants or in the analysis.

- Total with need: all participants assessed to have need of the relevant AP. Some studies consider all participants with impairment/FD as needing an AP.

- Total with AP: all participants who already have an AP. Most included vision AP studies reported on vision assessments done at 6 m. Alternative definitions (eg, 20 ft, log MAR) were converted to 6 m using the NIDEK conversion chart.¹⁰ For distance vision studies, prevalence estimates for uncorrected and undercorrected refractive error were also extracted, as these equate to unmet and undermet need for glasses, respectively. Results for ‘refractive error’ only (ie, without specifying uncorrected or undercorrected) were not extracted.

**Risk of bias in individual studies**

The Critical Assessment Tool for Prevalence Studies from the Joanna Briggs Institute (JBI) was used to evaluate all included full texts.¹⁵ We adapted this tool by adding a 10th criterion: ‘The study describes its ethical approval, including how consent was obtained from participants’. We present each study’s summary score and specific missing checklist criteria (online supplemental appendix 5).

This review was not registered with PROSPERO due to its relation to the scoping review,⁹ which necessitated the extraction of some overlapping systematic review data during the scoping review process. PROSPERO does not register scoping reviews and will not register systematic reviews which have already begun data extraction.

**Role of the funding source**

The funder of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report.

**Patient and public involvement**

Patients and the public were not involved in any way in this research.

**RESULTS**

This section first details overall study selection and characteristics. Next, results including AP indicators are presented for each AP, grouped by functional domain.
Study selection

Of 14,898 unique records identified, 1,238 abstracts mentioned AT and/or FD (JD). Ten per cent (n=1336) of discarded records were reviewed by a second author (CH, DB and SP) with 100% agreement. Seven reviews were identified at this stage and cross-referenced, adding 22 abstracts (JD, DB and ES). Of 1,260 total abstracts, 514 met inclusion criteria, determined by two authors (JD, DB, VDR, SP, CH and ES). Following full-text review, 207 articles met inclusion criteria (with 96% inter-rater agreement) (JD, DB, VDR and ES). Studies excluded at this stage are listed in online supplemental appendix 6. Figure 1 details the full review process. Corresponding authors were contacted for all articles missing full texts (initially n=85), resulting in seven additions (JD). All extracted data were double-checked (JD, AK, VDR, DB, ES, SP and CH).

Included study characteristics

All studies were published between 2002 and 2020. The cumulative frequency of studies published each year is shown by WHO region and AP type in figure 2A, B. The most represented region was the Western Pacific Region (WPR) (n=55, 27%), specifically China (n=29/55, 53%), followed by the Region of the Americas (AMR) (n=50, 24%), specifically the USA (n=27/50, 54%) and the Southeast Asian Region (SEAR) (n=46, 22%), specifically India (n=31/46, 67%).

Figure 1 Study selection. AP, assistive product; AT, assistive technology.

Figure 2 Cumulative publication frequency by WHO Region (A) and AP type (B). AP, assistive product; PDAs, personal digital assistants.
methods, and only one scoring below 7. By domain, the average JBI score ranged from 8.6 to 9.3. The most missed items were #2 (appropriate or well-described sampling of study participants) (n=30), #4 (study subjects and setting described in detail) (n=49) and our added #10 (consent and ethical approval detailed) (n=18) (online supplemental appendix 5).

AP access indicators
Overall, 656 AP access indicators were extracted. High-level results are presented for each AP, grouped by functional domain (tables 2–5) with all indicators from each study listed in online supplemental appendices 7-11. Studies reporting data, which could be disaggregated by comparable need indicators, are also included in figure 3A–E and online supplemental appendix 12.

### Hearing
In total, 25 studies (12%) provided 62 indicators on hearing aid access, detailed in table 2 and online supplemental appendix 7.16–40 Nearly all were based on primary (n=10, 40%) or secondary analyses (n=14, 56%) of cross-sectional studies. The majority (n=18, 72%) used multiple assessment approaches, while self-report was exclusively used by 4 (16%) and clinical assessment by 2 (8%). All but one study38 assumed all participants identified as

### Table 2

| Study design | Cohort | Cross-sectional | Mixed-methods | Secondary cross-sectional |
|--------------|--------|-----------------|---------------|--------------------------|
| N            | 1      | 9               | 1             | 14                       |
| %            | 4%     | 36%             | 4%            | 56%                      |

| Assessment approaches | Clinical only | Self-report only | Functional only | Clinical and self-report | Clinical and functional | Other combination | Secondary sources (multiple) |
|------------------------|---------------|------------------|-----------------|--------------------------|------------------------|---------------------|-----------------------------|
| N                      | 2             | 4                | 0               | 14                       |
| %                      | 8%            | 16%              | 0%              | 56%                      |

Participants (N)*<500 500–999 1000–4999 5000–24 999 25 000 Not available
| N | 3 | 1 | 11 | 2 | 3 | 4 | 1 | 25 |
| % | 12% | 4% | 44% | 8% | 12% | 16% | 4% | 100% |

Age (years) included†Under 15 <15 to 85+ 15 to 85+ 40 to 85+ 65 to 85+ Over 85 –
| N | 1 | 1 | 5 | 5 | 13 | 1 | 25 |
| % | 4% | 4% | 20% | 20% | 52% | 4% | 100% |

Functioning difficulty or impairment definition
| Use of AP | Reported activity limitations | Clinical threshold | Combination |
|-----------|-------------------------------|--------------------|-------------|
| N        | 3 | 5 | 14 | 3 | 3 | 25 |
| %        | 12% | 20% | 56% | 12% | – | – |

WHO Region
| AFR | AMR | EMR | EUR | SEAR | WPR | Global |
|-----|-----|-----|-----|------|-----|--------|
| N   | 3   | 10  | 1   | 8    | 3   | 1   |
| %   | 11% | 29% | 3%  | 24%  | 9%  | 24%  |

AP access indicator
| Total need | Met need | Unmet need | Undermet need | Coverage | Use | Has AP |
|------------|---------|------------|---------------|----------|-----|--------|
| N          | 7 | 1 | 17 | 0 | 2 | 26 | 9 | 62 |
| %          | 11% | 2% | 27% | 0% | 3% | 42% | 15% | 100% |

Indicator denominator
| Total with/using AP | Total with need | Total with functioning difficulty | Total participants | Total population |
|---------------------|-----------------|-----------------------------------|--------------------|------------------|
| N                   | 1              | 20                                | 15                 | 24               | 2                | –                | –                |
| %                   | 2%             | 32%                               | 24%                | 39%              | 3%               | –                | –                |

*Participants (N) ranged from 379 to 4 552 000 for this domain.
†Age group boundaries varied considerably by study; studies are sorted into categories that most closely represent their included age boundaries.
AFR, African Region; AMR, Region of the Americas; AP, assistive product; EMR, Eastern Mediterranean Region; EUR, European Region; JBI, Joanna Briggs Institute; SEAR, Southeast Asian Region; WPR, Western Pacific Region.
having a hearing difficulty also needed a hearing aid (ie, prevalence of hearing difficulty equals hearing aid need were the same). The proportion of participants with hearing difficulty who were using hearing aids ranged from 4.5%³⁸ to 47.5%,³⁴ although the definition of hearing difficulty varied between these studies (online supplemental appendix 7). Ten studies across 17 settings informed on total need. Figure 3A demonstrates high unmet need for hearing aids, with most settings (n=16, 89%) showing over 60% unmet need (ie, >60% of people assessed to need a hearing aid did not have one). All of these studies reported unmet need, but only one also reported met need³³ while the others substituted AP use.

### Mobility

Fifteen studies (7%) reported 42 access indicators for mobility APs, including prosthetics, motorised and manual wheelchairs. Characteristics are included in table 3 and all indicators in online supplemental appendix 8.¹⁷ ²² ²⁵ ²⁷ ³⁰ ⁴⁰–⁴⁹ Most mobility AP studies (n=11, 73%) were secondary analyses of national-level surveys/censuses. Six studies relied entirely on

---

**Table 3 Mobility AP studies and indicators**

| Study design   | Cohort | Cross-sectional | Mixed-methods | Secondary cross-sectional | Clinical and self-report | Clinical and functional | Other combination | Secondary sources (multiple) |
|----------------|--------|-----------------|---------------|---------------------------|--------------------------|------------------------|-------------------|-----------------------------|
| N              | 0      | 3               | 1             | 11                        | 73%                      | 0%                     | 7%                | 100%                        |
| %              | 0%     | 20%             | 7%            | 73%                       | 0%                       | 0%                     | 7%                | 100%                        |
| Assessment approaches | Clinical only | Self-report only | Functional only | Clinical and self-report | Clinical and functional | Other combination | Secondary sources (multiple) |
| N              | 1      | 9               | 0             | 4                         | 0                        | 1                      | 0                 | 15                          |
| %              | 7%     | 60%             | 0%            | 27%                       | 0%                       | 7%                     | 0%                | 100%                        |
| Participants (N)* | <500  | 500–999         | 1000–4999     | 5000–9999                 | 10000–24 999             | >25000                 | Not available     |
| N              | 0      | 1               | 4             | 4                         | 2                        | 4                      | 0                 | 15                          |
| %              | 0%     | 7%              | 27%           | 27%                       | 13%                      | 27%                    | 0%                | 100%                        |
| Age (years) included† | Under 15 | <15 to 85+ | 15 to 85+ | 40 to 85+ | 60 to 85+ | Over 85 | –                  |
| N              | 1      | 3               | 5             | 0                         | 5                        | 1                      | –                 | 15                          |
| %              | 7%     | 20%             | 33%           | 33%                       | 33%                      | 7%                     | –                 | 100%                        |
| JBI score      | <7     | 7               | 8             | 9                         | 10                       | –                      | –                 | –                           |
| N              | 0      | 0               | 3             | 5                         | 7                        | –                      | –                 | 15                          |
| %              | 0%     | 0%              | 20%           | 33%                       | 47%                      | –                      | –                 | 100%                        |
| Mobility functioning difficulty or impairment definition | Use of AP | Reported activity limitations | Clinical threshold | Combination |
| N              | 7      | 6               | 0             | 2                         | –                       | –                      | –                 | 15                          |
| %              | 47%    | 40%             | 0%            | 13%                       | –                       | –                      | –                 | 100%                        |
| WHO Region     | AFR    | AMR             | EMR           | EUR                       | SEAR                     | WPR                    | Global            |
| N              | 2      | 10              | 0             | 2                         | 2                       | 1                      | 0                 | 17                          |
| %              | 12%    | 59%             | 0%            | 12%                       | 12%                     | 6%                     | 0%                | 100%                        |
| AP access indicator | Total need | Met need | Unmet need | Undermet need | Coverage | Use | Has AP |
| N              | 3      | 0               | 6             | 1                         | 2                       | 26                     | 4                 | 42                          |
| %              | 7%     | 0%              | 14%           | 2%                        | 5%                      | 62%                    | 10%               | 100%                        |
| Indicator denominator | Total with/ using AP | Total with functioning difficulty | Total participants | Total population | – | – |
| N              | 3      | 2               | 12            | 19                        | 6                       | –                      | –                 | 42                          |
| %              | 7%     | 5%              | 29%           | 45%                       | 14%                     | –                      | –                 | 100%                        |

*Participants (N) ranged from 839 to 66 410 for this domain.
†Age group boundaries varied considerably by study; studies are sorted into categories that most closely represent their included age boundaries. AFR, African Region; AMR, Region of the Americas; AP, assistive product; EMR, Eastern Mediterranean Region; EUR, European Region; JBI, Joanna Briggs Institute; SEAR, Southeast Asian Region; WPR, Western Pacific Region.
self-reported assessment of activity limitation and/or AP need and seven used self-reported AP use to approximate functioning difficulty or impairment prevalence. AP use was the most reported indicator (n=26/42, 62%). Among the total with mobility difficulty, use of any type of mobility AP ranged from 0.9% (both prosthetics and motorised wheelchairs) to 17.6% (manual/unspecified wheelchairs) (online supplemental appendix 8).

Only one clinical impairment assessment study presented AP indicators allowing disaggregation of total need, showing high unmet need (>65%) for manual wheelchairs in two settings among those who needed the AP (figure 3C).

### Vision

Vision results are presented in three categories: near/reading glasses (n=35), distance glasses (n=31) and bifocal/combined/ unspecified (‘grouped’) glasses (n=124). High-level results for near and distance glasses are combined in table 4, with specific results for each type described separately in-text. All included studies and indicators are available for near and distance glasses in online supplemental appendix 9 and grouped glasses in online supplemental appendix 10.

#### Table 4 Near and distance glasses studies and indicators

| Study design | Cohort | Cross-sectional | Mixed-methods | Secondary cross-sectional | N | % |
|--------------|--------|-----------------|--------------|---------------------------|---|---|
| N            | 1      | 46              | 0            | 5                         | – | – |
| %            | 2%     | 88%             | 0%           | 10%                       | – | – |
| Assessment approaches | Clinical only | Self-report only | Functional only | Clinical and self-report | Clinical and functional | Other combination | Secondary sources (multiple) | – | – |
| N            | 18     | 2               | 30           | 0                         | 0 | 2 |
| %            | 35%    | 4%              | 58%          | 0%                        | 0%| 4% |
| Participants (N)* | <500 | 500–999         | 1000–4999    | 5000–9999                 | 10000–24999 | >25000 | Not available | – | – |
| N            | 3      | 6               | 24           | 10                        | 6 | 2 |
| %            | 6%     | 12%             | 46%          | 19%                       | 12%| 4% |
| Age (years) Included† | Under 15 | <15 to 85+ | 15 to 85+ | 40 to 85+ | >85+ | >85+ | Other | – | – |
| N            | 2      | 7               | 1            | 28                        | 8 | 6 |
| %            | 4%     | 13%             | 2%           | 15%                       | 15%| 0% |
| JBI score | <7    | 7               | 8            | 9                         | 10 | – |
| N            | 0      | 1               | 5            | 19                        | 27 | – |
| %            | 0%     | 2%              | 10%          | 37%                       | 52%| – |
| Vision functioning difficulty or impairment definition | Use of AP | Reported activity limitations | Clinical threshold | Combination | – | – |
| N            | 1      | 0               | 44           | 7                         | – | – |
| %            | 2%     | 0%              | 85%          | 13%                       | – | – |
| WHO Region | AFR    | AMR             | EMR          | EUR                       | SEAR| WPR| Global | – | – |
| N            | 20     | 23              | 4            | 11                        | 27 | 17 |
| %            | 19%    | 22%             | 4%           | 11%                       | 26%| 16% |
| AP access indicator | Total need | Met need | Unmet need | Undermet need | Coverage | Use | Has AP | Uncorrected RE | Undercorrected RE | N | % |
| N            | 11     | 40              | 61           | 8                         | 29 | 43 |
| %            | 5%     | 17%             | 26%          | 3%                        | 12%| 18% |
| Indicator denominator | Total with/ using AP | Total with | Total with functioning difficulty | Total participants | Total population | Total with unmet need | – | – |
| N            | 10     | 58              | 61           | 81                        | 22 | 1 |
| %            | 4%     | 25%             | 26%          | 35%                       | 9% | 0% |

*Participants (N) ranged from 134 to 3,983,541 for this domain.
†Age group boundaries varied considerably by study; studies are sorted into categories that most closely represent their included age boundaries.
AFR, African Region; AMR, Region of the Americas; AP, assistive product; EMR, Eastern Mediterranean Region; EUR, European Region; JBI, Joanna Briggs Institute; RE, Refractive Error; SEAR, Southeast Asian Region; WPR, Western Pacific Region.
Thirty-five studies (17%) provided 126 indicators for near glasses (table 4). Most were primary cross-sectional (n=32; 91%) and used a combination of clinical and self-reported assessment data (n=22; 63%), while 11 (31%) used clinical assessment data only. The most reported indicators were unmet (n=49; 38%) and met need (n=30; 24%). Near glasses use among individuals with vision difficulty ranged from 0.1% to 89.5% (online supplemental appendix 9).

Table 5 Grouped and cognitive AP studies and indicators

| Study design  | Cohort | Cross-sectional | Mixed-methods | Secondary cross-sectional | – | – | – | Total |
|---------------|--------|-----------------|---------------|--------------------------|---|---|---|-------|
| N             | 0      | 17              | 1             | 6                        | – | – | – | 24    |
| %             | 0%     | 71%             | 4%            | 25%                      | – | – | – | 100%  |
| Assessment approaches | Clinical only | Self-report only | Functional only | Clinical and self-report | Clinical and functional | Other combination | Secondary sources (multiple) | N | % | 4% | 88% | 0% | 4% | 0% | 4% | 0% | 100% |
| Participants (N)* | <500 | 500–999 | 1000–4999 | 5000–9999 | 10000–24 999 | >25000 | Not available | N | % | 0% | 3 | 7 | 5 | 5 | 4 | 0 | 24 |
| Age (years) included† | Under 15 | <15 to 85+ | 15 to 85+ | 40 to 85+ | 60 to 85+ | Over 85 | Other | N | % | 0% | 16 | 5 | 0 | 2 | 0 | 1 | 24 |
| JBI score | <7 | 7 | 8 | 9 | 10 | – | – | N | % | 0% | 2 | 5 | 10 | 7 | – | – | 24 |
| % | 0% | 8% | 21% | 42% | 29% | – | – | 100% |
| Functioning difficulty or impairment definition | Use of AP | Reported activity limitations | Clinical threshold | Combination | – | – | – | – |
| N | 3 | 21 | 0 | 0 | – | – | – | 24 |
| % | 13% | 88% | 0% | 0% | – | – | – | 100% |
| WHO Region | AFR | AMR | EMR | EUR | SEAR | WPR | Global | N | % | 56% | 28% | 4% | 0% | 8% | 4% | 0% | 100% |
| AP access indicator | Total need | Met need | Unmet need | Undermet need | Coverage | Use | Has AP | N | % | 5% | 10% | 21% | 2% | 0% | 57% | 5% | 100% |
| Indicator denominator | Total with/using AP | Total with need | Total with functioning difficulty | Total participants | Total population | – | – | N | % | 2% | 12% | 67% | 19% | 0% | – | – | 100% |

*Participants (N) ranged from 505 to 393,949 for this domain.
†Age group boundaries varied considerably by study; studies are sorted into categories that most closely represent their included age boundaries.
AFR, African Region; AMR, Region of the Americas; AP, assistive product; EMR, Eastern Mediterranean Region; EUR, European Region; JBI, Joanna Briggs Institute; SEAR, Southeast Asian Region; WPR, Western Pacific Region.
**Figure 3** Need indicators for hearing aids (A), manual wheelchairs (B), near glasses (C), distance glasses (D) and grouped APs (E). HI, High-Income; SS, Sub-Saharan.
difficulty seeing, use of distance glasses ranged from 0.4% to 55.2% (online supplemental appendix 9). Eleven studies provided total need indicators across 12 settings, the majority (n=8/12; 67%) of which reported an unmet need for distance glasses of >60% among those who needed the AP (figure 3D).

Grouped APs and cognitive

Twenty-four studies (12%) presented 42 indicators for grouped APs, with one study also presenting a cognitive AP indicator for PDAs; characteristics for all grouped AP studies are described in table 5 with all indicators included in online supplemental appendix 11. Nearly all (n=21; 88%) used only self-reported activity limitations to identify impairment or FD. ‘AP use’ was the most commonly reported indicator in the grouped domain (n=24/42, 57%), with the proportion of participants with FD using any AP ranging from 2.8% to 94.8% (online supplemental appendix 11). In three of five studies presenting total need indicators, unmet need for APs was >60% among those who needed APs (figure 3E).

DISCUSSION

AT is gaining recognition on the international global health agenda, as evidenced in this systematic review by the increasing frequency of publications from 2000 to 2020. However, many data gaps have not been addressed. During this period, 76% (n=158) of the 207 articles reported all or in part on glasses, with fewer articles available for the other APs, emphasising data gaps in hearing, mobility and especially cognitive functional domains. Older adults (65+ years) were more often included in studies than children under 12 years, and <25% of studies focused exclusively on young children, making it challenging to identify disparities in AP need based on age. This review also highlights the heterogeneity in study design and reporting that has led to a lack of standardisation in population-based AP data collection efforts and limits comparability between settings. Total need indicators were reported from 84 study settings, the majority of which (n=57/84, 68%) reported unmet need >60% among all participants with AP need in each functional domain and in all country income contexts. Total need estimates were also commonly reported across all functional domains except mobility, though functional domains were not equally represented in these studies.

AP indicators were often used variably in the literature. The prevalence of FD was frequently equated to AP need, which can overestimate/underestimate true need and coverage. This approach typically lacks a holistic assessment of AP need since it does not account for important data about an individual’s personal factors, including their specific health needs, activities, participation and environmental contexts. All but one mobility study made this assumption and relied solely on self-reported assessments, which can be limited by participants’ poor awareness of APs or underlying causes for FD, further misestimating need. ‘AP use’ or ‘use’ were also used to approximate ‘met need’ for an AP; all hearing aid studies indicating need reported ‘use’ in lieu of met need (excepting one). This substitution limits understanding of AP need in multiple ways: in the literature, the ‘use’ indicator has included the use of APs that are inappropriate (‘met need’) and APs that might be broken and/or inappropriate (‘undermet need’), which obfuscates remaining need. Denominators used when calculating indicators also varied considerably, encompassing individuals with need, functioning difficulty, included in the study, or extrapolated to the total population. Though the latter can provides useful measures for drawing international comparisons and evaluating trends over time, the variation in denominators overall limits comparability across studies. Each has its use in a comprehensive evidence basis, but more comparable methodology and reporting are needed to improve understanding of population-level need.

Self-reported assessments were typically employed in functional domains where a large sample size was needed and/or the relationship between the individual’s need and a specific AP is complex (eg, mobility or cognition), or multiple APs were considered (eg, grouped APs). Subsequently, clinical impairment and/or functional assessment for all participants was often not feasible. For example, most of the reviewed mobility studies were secondary data analyses, with over half using censuses or national health studies (n=10/15; 67%), while mobility studies that collected primary data tended to have very low numbers of individuals assessed as needing or already using the AP, ranging from 0 to 186 individuals. Additionally, most studies reporting on grouped APs relied exclusively on self-reported assessment data (n=21/24; 88%). Clinical impairment assessments produce more standardised, comparable data, yet do not always capture personal factors, which are also necessary to holistically evaluate need. This demonstrates the importance of employing multiple types of data in recommending appropriate AT.

While some established datasets based on universal care/centralised health record systems collect potentially impactful population-level data on AP users, these data do not necessarily include everyone. Relying exclusively on these data would miss individuals obtaining their APs by other means, such as private purchase or through the non-government sector. This missing data gap will be even more pronounced where government-led AT provision is more limited. Primary cross-sectional surveys can be helpful to address this gap, yet these surveys can be resource intensive, lack comparability and generalisability, and may not produce timely data needed by AT stakeholders. Our literature presentation >150 studies from LMICs, which generate valuable learnings across the sector overall. However, when narrowing to AP-specific or country-specific data, the evidence base drastically decreases, showing the limitations of relying exclusively on few cross-sectional surveys.
and demonstrates that the largest knowledge gaps are in areas where access to APs is lowest.

Collating this critical body of work to extract sector-wide learnings has been broached, in parts, by other reviews commissioned by the Lancet Global Health,224 the WHO,3 9 225 and development-focused institutes/governmental departments.226 227 The WHO papers cited heterogeneous approaches to assessment,3 9 225 severity of FD for inclusion,9 225 and sampling source demographics,3 9 225 as main challenges to interpreting results across publications, which mirrored our data extraction and presentation experience. Population-level data are overall extremely limited, and findings on need must be interpreted with caution. Appropriate research methods must also be used for this sector—RCTs are often unsuitable for AT interventions,3 and based on available data, different approaches may be more effective than others.9

Key gaps in the AT sector described in this discussion are emphasised when considering other AT reviews. Crucial research into effectiveness and follow-up of AT interventions is limited.9 225–227 Our review similarly found this, as most primary and secondary studies were cross-sectional and did not incorporate any follow-up data collection. Limited awareness of AT demand and effectiveness was a commonly cited barrier to expanding AT production and access.226 227 Often, available data go unused226 or are not collected alongside quality-of-life indicators.226 Furthermore, standardised impact measurement approaches are also needed.3 9 225 Regarding all types of information relevant to AT, including need indicators, supply and demand data, and product designs, more substantial diffusion is hindered by the fragmented nature of available information.226

We have four main recommendations following our comprehensive review. First, considering the methodological and reporting variation between studies, we recommend establishing a global minimum AP dataset allowing researchers to address specific questions and compare evidence. This dataset should include the following: (1) standardised measures to determine individual need for an AP; (2) standardised APs (eg, APLs),10 228 (3) standardised AP access indicators (as presented in this review) and (4) standardised approaches to measuring them. Second, we recommend the collection and use of data that holistically considers an individual’s personal and environmental factors when assessing their capacity to benefit from an AP. As more holistic measurement methodology is developed, it is critical that it is tested and adapted for diverse contexts, especially LMICs. Third, modules collecting data to inform AP indicators should be included in established population surveys to maximise existing data collection methods and enable more nuanced secondary analyses. This can be supported by working with national statistics offices in both high and LMIC countries. Finally, differentiation should be made between the total using an AP, and within that value, the total with met need. This can highlight undermet needs among AP users, which provides further data about the setting and/or population for which specific APs are not fully appropriate. To begin to collate this dataset, a global AT data portal229 accompanying this review will make all extracted study data available and more accessible. This portal will also serve as a place to host future data, employing features to map evidence and provide context across disciplines to support knowledge sharing in this sector.

Our large-scale review captured >200 studies and benefited from including five APs across four functional domains, with a broadly inclusive search string and list of article sources. Data extraction criteria were developed to accommodate substantial variation in results reporting, so as much relevant data as possible could be considered, allowing us to extract >650 indicators. Through data extraction, we identified study settings, impairment/FD thresholds and denominators (among other factors) to ensure our comparisons and conclusions are appropriate.

However, this review has several limitations. Given the breadth of literature, we searched terms for FD rather than listing specific health conditions (online supplemental appendix 2), as there is no established list of conditions within each domain/relevant to each AP. Studies may have been missed that focused on specific health conditions without mentioning FD or APs in the title/abstract. This likely occurred for the mobility and cognitive domains, given these are less well defined in terms of which conditions could relate to certain APs. This also means we could not explore the variation in need for APs within a functional domain by certain conditions or pathologies. We also limited the review to five specific APs, while the WHO APL includes 50. Furthermore, a meta-analysis of indicators and exploration into their disaggregation by demographic factors (eg, sex, income, and education) was precluded from the remit of this review due to wide variation in methods/reporting. Finally, some vision studies also reported visual acuity measures, but extracting indicators based on these measures required clinical judgements and assumptions outside the remit of this review. Overall, future domain-specific research is recommended to address each of these limitations, including additional cognitive APs, with appropriate detail to identify sub-population-level disparities in AP access.

CONCLUSION

This review highlights high unmet AP need across different settings, demonstrating the need to prioritise and expand access to AT globally. It also highlighted key AP research gaps in available literature, including lack of standardised and comparable data collection and reporting methods, particularly in LMICs. These gaps must be addressed so data collection efforts can identify areas with high need and inform, monitor, and evaluate AP service planning and delivery. Improving global access to these life-changing products is essential to each sustainable development goal and our accompanying
data portal\cite{1} will ensure this review is used to its fullest potential in support of this aim.

**Twitter** Dorothy Boggs @boggs_dorothy

**Acknowledgements** Authors are grateful to the help of many colleagues: Priya Morjaria and Ian McCormick for visual acuity expertise and Ben Duke for preliminary data extraction.

**Contributors** This research was conceptualised by JD and CH, with funding acquired by CH. The investigation was conducted by JD, with input from DB, SP and CH. JD, DB, SP, VDR, ES and CH are responsible for the methodology. FR is responsible for project administration. JD and WB are responsible for software design and maintenance. Data curation was done by JD, DB, VDR, ES and AK. Formal analysis was carried out by JD with input from DB and SP. Data were validated by JD, AK, VDR, ES, SP, DB and CH. Visualisations were designed and executed by JD, with input from DB and SP. The original draft was written by JD with input from DB and SP. Reviewing and editing was done by JD, DB, SP, VDR, ES and CH, with input from AK and FR. The overall project was supervised by DB, SP and CH. JD is acting as guarantor.

**Funding** The research in this paper was made possible by funding from the Foreign, Commonwealth and Development Office, UK, through the 4AT2030 Programme, led by the Global Disability Innovation Hub (project number: 300 815 (previously 2 01 879–108)).

**Competing interests** None declared.

**Patient consent for publication** Not applicable.

**Ethics approval** Ethical approval was not required for this review.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available in a public, open access repository. All data relevant to the study are included in the article or uploaded as supplementary information. The study protocol is currently available at https://at2030.org/estimating-need-and-coverage-for-five-priority-assistive-products/ All data extracted for this review will be publicly available in the AT Data Portal, available at https://at2030.org/at-data-portal/map/ from March 2022.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**
Jamie Danemayer http://orcid.org/0000-0002-0060-5160
Dorothy Boggs http://orcid.org/0000-0001-5380-2785
Felipe Ramos-Barajas http://orcid.org/0000-0001-8729-2971

**REFERENCES**

1. WHO. Health systems strengthening glossary, 2011. Available: https://www.who.int/healthsystems/Glossary_January2011.pdf
2. Cieza A, Causey K, Kamenov K, et al. Global estimates of the need for rehabilitation based on the global burden of disease study 2019: a systematic analysis for the global burden of disease study 2019. *Lancet* 2021;396:2006–17.
3. Matter R, Harniss M, Oderud T, et al. Assistive technology in resource-limited environments: a scoping review. *Disabil Rehabil Assist Technol* 2017;12:105–14.
4. Prvu Bettger J, Thoumi A, Marquevich V, et al. COVID-19: maintaining essential rehabilitation services across the care continuum. *BMJ Glob Health* 2020;5:e002670.
5. Rajan S, Khunti K, Alwan N. In the wake of the pandemic: preparing for long COVID. *World Health Organization*, 2021.
6. Briggs A, Vassall A. Count the cost of disability caused by COVID-19. *Nature* 2021;593:502–5.
7. Tebbutt E, Brodmann R, Borg J, et al. Assistive products and the sustainable development goals (SDGs). *Global Health* 2016;12:1–6.
8. Savage M, Tyler N, Seghers F. Applying market shaping approaches to increase access to assistive technology: summary of the wheelchair product narrative, 2019.
9. Danemayer J, Boggs D, Polack S, et al. Measuring assistive technology supply and demand: a scoping review. *Assist Technol* 2021;33:35–49.
10. WHO. Priority assistive products list (APL): improving access to assistive technology for everyone, everywhere. Geneva, 2016.
11. Atscale global partnership. Available: https://atscale2030.org/ [Accessed 12 Nov 2021]
12. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71.
13. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile APP for systematic reviews. *Syst Rev* 2016;5:210.
14. NIDDK Co. Conversion table for representation of visual acuity. Available: https://www.niddk-intl.com/visual_acuity.html [Accessed 19 Jul 2021].
15. University of Adelaide. Critical appraisal tools | Joanna Briggs Institute, 2020. Available: https://jbi.global/critical-appraisal-tools [Accessed 12 Jul 2021].
16. Muge E. Screening for disability in a community: the ‘ten questions’ screen for children, in Bondo, Kenya. *Afr Health Sci* 2003;3:33–9.
17. Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the global burden of disease study 2015. *The Lancet* 2016;388:1545–602.
18. Vuorio A, Sorri M, Nuouja I. Costs of hearing aid rehabilitation in two Finnish hearing centres. *Audiol Med* 2004;2:236–40.
19. Nash SD, Cruickshanks KJ, Huang G-H, et al. Unmet hearing health care needs: the Beaver dam offspring study. *Am J Public Health* 2013;103:1134–9.
20. Dawes P, Fortnum H, Moore DA, et al. Hearing in middle age: a population snapshot of 40– to 69-year olds in the United Kingdom. *Ear Hear* 2014;35:e44–51.
21. Sawyer CS, Armitage CJ, Munro KJ, et al. Correlates of hearing aid use in UK adults: self-reported hearing difficulties, social participation, living situation, health, and demographics. *Ear Hear* 2019;40:1061–8.
22. Boggs D, Kuper H, MacTaggart I. Estimating assistive technology need through population-based surveys: an analysis of data from Cameroon and India. In: Layton N, Borg J, eds. *Global perspectives on assistive technology: proceedings of the GREAT Consultation*. World Health Organization, 2019: 52–78.
23. Orji A, Kamenov K, Dirac M, et al. Global and regional needs, unmet needs and access to hearing aids. *Int J Audiol* 2020;59:166–72.
24. Gondim LMA, Balen SA, Zimmermann KJ, et al. Study of the prevalence of impaired hearing and its determinants in the city of Itajaí, SANTA Catarina state, Brazil. *Braz J Otorhinolaryngol* 2017;83:27–34.
25. Danquah L, Brus A. Representation and evaluation of disability in Haiti (Port-au-Prince) 2012. London, UK, 2013.
26. von Gablenz P, Hoffmann E, Holube I. Prevalence of hearing loss in northern and southern Germany. *HNO* 2017;65:130–5.
27. Berardi A, Smith EM, Miller WC. Assistive technology use and unmet need in Canada. *Disabil Rehabil Assist Technol* 2021;16:851–6.
28. Angara P, Tang DC, Snapp H. Factors associated with delayed hearing evaluation on US adults. *Otolaryngol Head Neck Surg* 2018;159:P268.
29. Li C-M, Zhao G, Hoffman HJ, et al. Hearing disability prevalence and risk factors in two recent national surveys. *Am J Prev Med* 2018;55:326–35.
30. Pryor W, Nguyen L, Islam QN, et al. Unmet needs and use of assistive products in two districts of Bangladesh: findings from a household survey. *Int J Environ Res Public Health* 2018;15:1–13.
31. Moon IJ, Baek SY, Cho Y-S. Hearing aid use and associated factors in South Korea. *Medicine* 2015;94:e1580.
32. Uptonah B, Schneider J, Hartley D, et al. Incidence and predictors of hearing aid use and ownership among older adults with hearing loss. *Ann Epidemiol* 2011;21:497–506.
33 Corna LM, Wade TJ, Streiner DL, et al. Corrected and uncorrected hearing impairment in older Canadians. Gerontology 2009;55:468–76.
34 Mitchell P, Gopinath B, Wang JJ, et al. Five-year incidence and progression of hearing impairment in an older population. Ear Hear 2011;32:251–7.
35 Kim J-S. Prevalence and factors associated with hearing loss and hearing aid use in Korean elders. Iran J Public Health 2015;44:308–17.
36 SZMS M, Maarmor N, Ishak WS. Hearing loss and risk factors among community Dwelling older adults in Selangor (the Hilang Penderangan DAN Faktor Risiko dalam Kalangan Warga Tua dalam Komuniti di Selangor). Sains Malaysiana 2016;45:1405–11.
37 Chang H-P, Ho C-Y, Chou P. The factors associated with a self-perceived hearing handicap in elderly people with hearing impairment—results from a community-based study. Ear Hear 2009;30:576–83.
38 López-Torres Hidalgo J, Boix Gras C, Téllez Lapeire J, et al. Functional status of elderly people with hearing loss. Arch Gerontol Geriatr 2009;48:85–92.
39 Bainbridge KE, Ramachandran V. Hearing aid use among older U.S. adults; the National health and nutrition examination survey, 2005-2006 and 2009-2010. Ear Hear 2014;35:289–94.
40 Dupraz J, Andersen-Ranberg K, Fons S, et al. Use of healthcare services and assistive devices among centenarians: results of the cross-sectional, international5-COOP study. BMJ Open 2020;10:e034296.
41 Giesbrecht EM, Smith EM, Mortenson WB, et al. Needs for mobility devices, home modifications and personal assistance among Canadians with disabilities. Health Rep 2012;154:9–16.
42 Smith EM, Giesbrecht EM, Mortenson WB, et al. Prevalence of wheelchair and scooter use among community-dwelling Canadians. Phys Ther 2016;96:1135–42.
43 Gale CR, Cooper C, Sayer AA. Prevalence of frailty and disability: findings from the English longitudinal study of ageing. Age Ageing 2015;44:162–5.
44 Gell NM, Wallace RB, LaCroix AZ, et al. Mobility device use in older adults and incidence of falls and worry about falling: findings from the 2011-2012 National health and aging trends study. J Am Geriatr Soc 2015;63:1609–17.
45 Iwashyna TJ, Christie JD. Low use of durable medical equipment by chronically disabled elderly. J Pain Symptom Manage 2007;33:324–30.
46 Wolf JL, Agree EM, Kasper JD. Wheelchairs, walkers, and canes: what does Medicare pay for, and who benefits? Health Aff 2005;24:1140–9.
47 Tataryn M, Polack S, Chokotho L, et al. Childhood disability in Malawi: a population based assessment using the key informant method. BMC Pediatr 2017;17:196.
48 Theis KA, Steimweg A, Helmick CG, et al. Which one? What kind? How many? Types, causes, and prevalence of disability among U.S. adults. Disabil Health J 2019;12:411–21.
49 Cormman JC, Friedman VA. Racial and ethnic disparities in mobility device use in late life. J Gerontol B Psychol Sci Soc Sci 2008;63:S34–41.
50 Azizoglu S, Crewe SR, Şerefhan F, et al. Evidence for the need for vision screening of school children in Turkey. BMC Ophthalmol 2017;17:230.
51 Marramula S, Keefe JE, Narasiah S, et al. Changing trends in the prevalence of visual impairment, uncorrected refractive errors and use of spectacles in Mahabubnagar district in South India. Indian J Ophthalmol 2013;61:755–8.
52 Muhit M, Minto H, Parvin A, et al. Prevalence of refractive error, presbyopia, and unmet need of spectacle care in a northern district of Bangladesh: rapid assessment of refractive error study. Ophthalmic Epidemiol 2018;25:126–32.
53 Chan VF, Mebratu G, Ramson P, et al. Prevalence of refractive error and spectacle care coverage in Zoba Ma’ekel Ethiopia: a rapid assessment of refractive error. Ophthalmic Epidemiol 2013;20:131–7.
54 Loughman J, Nxele LL, Faria C, et al. Rapid assessment of refractive error, presbyopia, and visual impairment and associated quality of life in Nampula, Mozambique. J Vis Impair Blind 2015;109:199–212.
55 Marramula S, Keefe JE, Rao GN. Uncorrected refractive errors, presbyopia and spectacle coverage: results from a rapid assessment of refractive error survey. Ophthalmic Epidemiol 2009;16:269–74.
56 Taylor HR, Xie Y, Fox S, et al. The prevalence and causes of visual loss in Indigenous Australians: the National Indigenous eye health survey. Med J Aust 2010;192:312–8.
57 Ramke J, Brian G, Nauduvitha T. Refractive error and presbyopia in timor-leste: the impact of 5 years of a national spectacle program. Invest Ophthalmol Vis Sci 2012;53:434–9.
58 Fricke TR, Tahhan N, Resnikoff S, et al. Global prevalence of presbyopia and vision impairment from uncorrected presbyopia: systematic review, meta-analysis, and modelling. Ophthalmology 2018;125:1492–9.
59 Casas Luque L, Naidoo K, Chan VF, et al. Prevalence of refractive error, presbyopia, and spectacle care coverage in Bogotá, Colombia: a rapid assessment of refractive error. Optom Vis Sci 2019;96:579–86.
60 Robinson B, Feng Y, Woods CA, et al. Prevalence of visual impairment and uncorrected refractive error - report from a Canadian urban population-based study. Ophthalmic Epidemiol 2013;20:123–30.
61 Umar MM, Muhammad N, Ahassan MB. Prevalence of presbyopia and spectacle correction coverage in a rural population of North West Nigeria. Clin Ophthalmalpalm 2015;5:1195–201.
62 Abdullah AS, Jadoon MZ, Akram M, et al. Prevalence of uncorrected refractive errors in aged 30 years and above in a rural population of Pakistan. J Ayub Med Coll Abbottabad 2015;27:8–12.
63 Laitinen A, Koskinen S, Härkänen T, et al. A nationwide population-based survey on visual acuity, near vision, and self-reported visual function in the adult population in Finland. Ophthalmology 2005;112:2227–37.
64 He M, Abdou A, Naidoo KS, et al. Prevalence and correction of near vision impairment at seven sites in China, India, Nepal, Nigeria, South Africa, and the United States. Am J Ophthalmol 2010;139:115–22.
65 He M, Abdou A, Ellwein LB, et al. Age-Related prevalence and Met need for correctable and uncorrectable near vision impairment in a multi-country study. Ophthalmology 2014;121:417–22.
66 Hookway LA, Frazier M, Rivera N, et al. Population-Based study of presbyopia in Nicaragua. Clin Exp Optom 2016;90:539–63.
67 Naidoo KS, Jaggernath J, Martin C, et al. Prevalence of presbyopia and spectacle coverage in an African population in Durban, South Africa. Optim Vis Sci 2013;90:1424–9.
68 Ntidie M, Abu SL, Kyei S, et al. Near vision spectacle coverage and barriers to near vision correction among adults in the Cape coast Metropolis of Ghana. Afr Health Sci 2017;17:549–55.
69 Sapkota YD, Dulal S, Pokharel GP, et al. Prevalence and correction of near vision impairment at Kaski, Nepal. Nepal J Ophthalmol 2012;4:17–22.
70 Uche N, Ezezorui I, Uche E, et al. Prevalence of presbyopia in a rural African community. Rural Remote Health 2014;14:2731.
71 Cheng F, Shan L, Song W, et al. Distance- and near-visual-spectacle coverage for rural Chinese adults in Kailu, inner Mongolia. Acta Ophthalmalpalm 2016;94:407–13.
72 Gupta N, Vashiit P, Malhotra S, et al. Rapid assessment of visual impairment in urban population of Delhi, India. PLOS One 2015;10:e0124206.
73 Lavieris HR, Omar F, Jecha H, et al. Presbyopic spectacle coverage, willingness to pay for near correction, and the impact of correcting uncorrected presbyopia in adults in Zamitar, East Africa. Invest Ophthalmol Vis Sci 2010;51:1234–41.
74 Lu Q, He W, Murthy GVS, et al. Presbyopia and near-visual impairment in rural Northern China. Invest Ophthalmol Vis Sci 2011;52:2300–5.
75 Manners SL, Romero FC, Smith NH, et al. Causes of visual impairment and common eye problems in northwest American Indians and Alaska natives. Am J Public Health 2005;95:881–6.
76 Marramula S, Madala SR, Rao GN. Prevalence of uncorrected refractive errors, presbyopia and spectacle care coverage in marine fishing communities in South India: rapid assessment of visual impairment (RAVI) project. Ophthalmic Physiol Opt 2012;32:149–55.
77 Marramula S, Narasiah S, Shekhar K, et al. Presbyopia, spectacle use and spectacle correction care coverage for near vision among cloth weaving communities in Prakasam district in South India. Ophthalmic Physiol Opt 2013;33:597–603.
78 Marramula S, Khanna RC, Narasiah S, et al. Prevalence of spectacle use in Andhra Pradesh, India: rapid assessment of visual impairment project. Clin Exp Optom 2014;42:227–34.
79 Marramula S, Khanna RC, Kunuku E, et al. Near visual impairment and spectacle care coverage in Telangana, India. Clin Exp Optom 2017;45:568–74.
80 Ramke J, Du Toit R, Palayag J, et al. Correction of refractive error and presbyopia in Timor-Leste. Br J Ophthalmol 2007;91:860–6.
81 Guntha CC, Berezinskaia Y, Furtado JM, et al. Presbyopia and ocular conditions causing near vision impairment in older adults from the Brazilian Amazon region. Am J Ophthalmol 2018;169:72–81.
Zebari A, et al. BMJ Global Health 2022;7:e007662. doi:10.1136/bmjgh-2021-007662

82 Shervin JC, Keefe JE, Kuper H, et al. Functional presbyopia in a rural Kenyan population: the unmet presbyopic need. Clin Exp Ophthalmol 2008;36:245–51.

83 Zebardast N, Friedman DS, Vitale S. The prevalence and demographic associations of presenting Near-Vision impairment among adults living in the United States. Am J Ophthalmol 2017;174:134–44.

84 Otte B, Woodward MA, Ehrlich JR, et al. Self-Reported eyeglass use by US Medicare beneficiaries aged 65 years or older. JAMA Ophthalmol 2018;136:1047–50.

85 Kodjebacheva G, Brown ER, Estrada L, et al. Uncorrected refractive error among first-grade students of different racial/ethnic groups in southern California: results a year after school-mandated vision screening. J Public Health Manag Pract 2011;17:499–505.

86 Naidoo KS, Chinanayi FS, Ramson P, et al. Rapid assessment of refractive error in the eThekwini Municipality of KwaZulu-Natal, Durban, South Africa. Clin Exp Optom 2016;39:360–5.

87 Goujon N, Brown CM, Xie J, et al. Self-Reported vision and health of Indigenous Australians. Clin Exp Ophthalmol 2010;38:796–804.

88 Vitale S, Cotch MF, Sperduto R, et al. Costs of refractive correction of distance vision impairment in the United States, 1999-2002. Ophthalmology 2006;113:2163–70.

89 Malhotra S, Kalavani M, Rath R, et al. Use of spectacles for distance vision: coverage, unmet needs and barriers in a rural area of North India. BMC Ophthalmol 2019;19:252.

90 Foreman J, Xie J, Keel S, et al. Treatment coverage rates for refractive error in the National eye health survey. PLoS One 2017;12:e0175353.

91 Shah SP, John MZ, Dineen B, et al. Refractive errors in the adult Pakistani population: the National blindness and visual impairment survey. Ophthalmic Epidemiol 2008;15:183–90.

92 Ramsewak SSA, Verlander N, Deo-mansingh F. National eye survey of Trinidad and Tobago: the prevalence and risk factors for refractive error. Investigative Ophthalmology and Visual Science 2016;57:3976.

93 Foreman J, Xie J, Keel S, et al. The prevalence and causes of vision loss in Indigenous and non-Indigenous Australians: the National eye health survey. Ophthalmology 2017;124:1743–52.

94 Gilbert C, McVicar GVS, Schmidt M, et al. Prevalence of refractive errors, and spectacle coverage in Sri Lankan adults: the Sri Lanka national survey of blindness and visual impairment. Ceylon Med J 2018;63:33.

95 Marmamula S, Khanna RC, Kunkuru E, et al. Population-Based assessment of prevalence and causes of visual impairment in the state of Telangana, India: a cross-sectional study using the rapid assessment of visual impairment (RAVI) methodology. BMJ Open 2016;6:e012617.

96 Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health 2017;5:e1221–34.

97 Malhotra S, Vashist P, Gupta N, et al. Prevalence and causes of visual impairment among adults aged 15–49 years in a rural area of north India – a population-based study. Indian J Ophthalmol 2018;66:951–6.

98 Murtthy GVS, Vashist P, John N, et al. Prevalence and causes of visual impairment and blindness in older adults in an area of India with a high cataract surgical rate. Ophthalmic Epidemiol 2010;17:185–92.

99 Zhao J, Ellwein LB, Cui H, et al. Prevalence of vision impairment in older adults in rural China: the China Nine-Province survey. Ophthalmology 2010;117:409–16.

100 Naël V, Moreau G, Monfermé S, et al. Exceptionally low prevalence of refractive error in children from Lao people’s Democratic Republic. Ophthalmology 2012;119:2021–7.

101 Hashim SE, Tan HK, Wan-Hazabbah WH. Prevalence of refractive error in Malay primary school children in suburban area of Kota Bharu, Kelantan, Malaysia. Annals of the Academy of Medicine Singapore 2008;37:940–6.

102 Aldebasih YH. Prevalence of correctable visual impairment in primary school children in Qassim Province, Saudi Arabia. J Ophthal 2010;7:168–78.

103 Choy BNK, You Z, MM, et al. Prevalence and associations of myopia in Hong Kong primary school students. Jpn J Ophthalmol 2020:64:437–49.

104 Harrington SC, Stack J, Saunders K, et al. Refractive error and visual impairment in Ireland schoolchildren. Br J Ophthalmol 2019;103:1112–8.

105 O’Donoghue L, McClelland JF, Logan NS, et al. Refractive error and visual impairment in school children in Northern Ireland. Br J Ophthalmol 2010;94:1159–65.

106 Al Wadaani FA, Amin TT, Ali A. Prevalence and pattern of refractive errors among primary school children in al Hassa, Saudi Arabia. Glob J Health Sci 2013:5:125–34.

107 Gupta A, Lal R, Mazra SR. Prevalence of refractive errors, color vision defects and other ocular disorders in school-going children: primary screening by school teachers. Journal International Medical Sciences Academy 2012:25:223–4.

108 Hameed A. Screening for refractive errors and visual impairment among school children in Kohat, Pakistan. Rawal Medical Journal 2010;41:437–40.

109 He M, Zeng J, Liu Y, et al. Refractive error and visual impairment in urban children in southern China. Invest Ophthalmol Vis Sci 2004;45:793–9.

110 He M, Xu J, Yin Q, et al. Need and challenges of refractive correction in urban Chinese school children. Optom Vis Sci 2005;82:26–44.

111 Kassa T, Alene GD. Prevalence of refractive errors in pre-school and school children of Debark and kola Diba towns, north-western Ethiopia. Ethiopian Journal of Health Development 2004;17:117–24.

112 Hu M, Zhou Y, Huang S, et al. Population prevalence of myopia, glasses wear and free glasses acceptance among minority versus Han schoolchildren in China. PLoS One 2019;14:e0215660.

113 Kaur G, Koshy J, Thomas S, et al. Vision screening of school children by teachers as a community based strategy to address the challenges of childhood blindness. J Clin Diagn Res 2016;10:NC09–14.

114 Dandona R, Dandona L, Srinivas M, et al. Refractive error in children in a rural population in India. Invest Ophthalmol Vis Sci 2010;51:212–8.

115 Falkenberg HK, Langaa T, Svanerud E. Vision status of children aged 7–15 years referred from school vision screening in Norway during 2003-2013: a retrospective study. BMC Ophthalmol 2019;19:1;N:PAG-PAG.

116 Syed B-P, Abuya Y, Pokhrel GP, et al. Refractive error and visual impairment in school-age children in Gombak district, Malaysia. Ophthalmology 2005;112:678–85.
Kedir J, Girma A. Prevalence of refractive error and visual impairment among rural school-age children of Goro District, Gurage zone, Ethiopia. *Ethio J Health Sci* 2014;24:353–8.

Pavithra MB, Hamsa L, Madhukumar S. Factors associated with spectacle-wear compliance among schoolchildren of 7-15 years in South India. *Int J Med Public Health* 2014;4:146.

Wang X, Yi H, Lu L, et al. Population prevalence of need for spectacles and spectacle ownership among urban migrant children in eastern China. *JAMA Ophthalmol* 2015;133:1399–406.

Yekta A, Fototghi A, Hashemi H, et al. Prevalence of refractive errors among schoolchildren in Shiraz, Iran. *Clin Exp Ophthalmol* 2010;38:242–8.

Zhu Z, Ellwein LB, Wang S, et al. Prevalence of refractive error and visual impairment among rural schoolchildren in two urban areas of Chile. *Clin Exp Optom* 2006;113:1567–73.

Barria F, Coma F, Muñoz J, et al. Prevalence of refractive error and spectacle coverage in schoolchildren in two urban areas of Chile. *Rev Panam Salud Publica* 2018;42:1–8.

Robaei D, Huynh SC, Kiley A, et al. Correctable and non-correctable visual impairment in a population-based sample of 12-year-old Australian children, *Am J Ophthalmol* 2006;142:112.

Robaei D, Kiley A, Rose KA, et al. Refractive error and patterns of spectacle use in 12-year-old Australian children. *Ophthalmology* 2008;115:1967–73.

Yamamah GAN, Talaat Abdel Alim AA, Mostafa YSED, et al. Prevalence of visual impairment and refractive errors in children of South Sinai, Egypt. *Ophthalmic Epidemiol* 2015;22:246–52.

Mehari ZA, Yimer AW. Prevalence of refractive errors among schoolchildren in rural central Ethiopia. *Clin Exp Optom* 2013;96:65–9.

Plainsi S, Moschandreas J, Nikolitisa P, et al. Myopia and visual acuity impairment: a comparative study of Greek and Bulgarian school children. *Ophthalmic Physiol Opt* 2009;29:312–20.

Sapkota YD, Adhikari BN, Pokharel GP, et al. The prevalence of visual impairment in schoolchildren of upper-middle socioeconomic status in Kathmandu. *Ophthalmic Epidemiol* 2008;15:17–23.

Salomão SR, Correia de Oliveira PJ, et al. Prevalence and causes of visual impairment in low-middle income school children in Sao Paulo, Brazil. *Invest Ophthalmol Vis Sci* 2008;49:4308–13.

AAEU, El-Wakeel AE, Mahran WM. Prevalence and risk factors of refractive errors among preparatory school students in Beni-Suef, Egypt. *Journal of Public Health* 2019;27:43–7.

Gao Z, Meng N, Muecke J, et al. Refractive error in schoolchildren in an urban and rural setting in Cambodia. *Ophthalmic Epidemiol* 2012;19:16–22.

Qian D-J, Zhong H, Li J, et al. Spectacles utilization and its impact on health-related quality of life among rural Chinese adolescents. *Eye* 2018;32:1879–85.

Ajiayebi AO, Ilawummi MA, Asoye AO, et al. Pattern of eye diseases and visual impairment among students in southwestern Nigeria. *Int Ophthalmol* 2007;27:287–92.

Congdon N, Wang Y, Song Y, et al. Visual disability, visual function, and myopia among rural Chinese secondary school children: the Xiangcheng Pediatric Refractive Error Study (X-PRES)--report 1. *Invest Ophthalmol Vis Sci* 2008;49:2888–94.

Congdon N, Zheng M, Sharma A, et al. Prevalence and determinants of spectacle nonwear among rural Chinese schoolchildren: the Xiangcheng pediatric refractive error study report 3. *Invest Ophthalmol Vis Sci* 2008;49:2891–902.

Li L, Song Y, Liu X, et al. Spectacle acceptance among secondary school students in rural China: the Xiangcheng Pediatric Refractive Error Study (X-PRES)--report 5. *Invest Ophthalmol Vis Sci* 2008;49:2895–902.

Zhang M, Li H, Yao W, et al. Visual morbidity due to inaccurate spectacles among school children in rural China: the see well to learn well project, report 1. *Invest Ophthalmol Vis Sci* 2009;50:2011–7.

He M, Huang W, Zheng Y, et al. Refractive error and visual impairment in school children in rural southern China. *Ophthalmology* 2007;114:793–9.

Abu EK, Yeoab AA, Ocansey S, et al. Epidemiology of ocular disorders and visual impairment among school pupils in the Cape coastal Metropolis, Ghana. *Br J Vis Impair* 2015;33:45–53.

Alsayeg A, Abu ASA, Fageh R, et al. The visual status of adolescents in Riyadh, Saudi Arabia: a population study. *Clin Ophthalmol* 2018;12:965–72.
Danemayer J, et al. BMJ Global Health 2022;7:e007662. doi:10.1136/bmjgh-2021-007662

181 Casson RJ, Newland HS, Muecke J, et al. Prevalence and causes of visual impairment in rural Myanmar: the Meiktila eye study. *Ophthalmology* 2007;114:2302–8.

182 Ezelum C, Razavi H, Sivasubramaniam S, et al. Refractive error in Nigerian adults: prevalence, type, and spectacle coverage. *Invest Ophthalmol Vis Sci* 2011;52:5449–56.

183 Marmamula S, Shekhar K, Banerjee S, et al. Population-Based assessment of unilateral visual impairment in the South Indian state of Andhra Pradesh: rapid assessment of visual impairment (RAVI) project. *Ophthalmic Epidemiol* 2015;22:171–5.

184 Marmamula S, Khanna RC, Kunuku E, et al. Spectacles use in a rural population in the state of Telangana in South India. *Indian J Ophthalmol* 2017;65:909–15.

185 Marmamula S, Challia R, Yellapragada S, et al. Temporal trends in the prevalence of refractive error and spectacle coverage in India. *Clin Exp Optom* 2020;103:693–8.

186 Marmamula S, Yellapragada S, Khanna RC. Population Based Assessment of Prevalence and Causes of Vision Impairment in the North-eastern State of Tripura, India - The Tripura Eye Survey. *Ophthalmology* 2020;27:283–8.

187 Premra R, George R, Sathyamangalam Ve R, et al. Comparison of refractive errors and factors associated with spectacle use in a rural and urban South Indian population. *Indian J Ophthalmol* 2008;56:139–45.

188 Tafida A, Kyari F, Abdull MM, et al. Poverty and blindness in Nigeria: results from the National survey of blindness and visual impairment. *Ophthalmic Epidemiol* 2015;22:333–41.

189 Zheng Y, Lavanya R, Wu R, et al. Prevalence and causes of visual impairment and blindness in an urban Indian population: the Singapore Indian eye study. *Ophthalmology* 2011;118:1798–804.

190 Pan C-W, Qian D-J, Sun H-P, et al. Visual impairment among older adults in a rural community in eastern China. *J Ophthalmol* 2016;2016:1–6.

191 Furtado JM, Banaszovsky A, Ferraz NN, et al. Prevalence and causes of visual impairment and blindness in adults aged 45 years and older from Parintins: the Brazilian Amazon region eye survey. *Ophthalmic Epidemiol* 2019;26:345–54.

192 Bastawrous A, Mathenge W, Foster A, et al. Prevalence and predictors of refractive error and spectacle coverage in Nakuru, Kenya: a cross-sectional, population-based study. *Int Ophthalmol* 2013;33:541–8.

193 Gallerreta M, Furtado JM, Lansingh VC, et al. Rapid assessment of avoidable blindness in Uruguay: results of a nationwide survey. *Rev Panam Salud Publica* 2014;36:219–29.

194 Lee L, D’Esposito F, Garaj J, et al. Rapid assessment of avoidable blindness in Papua New Guinea: a nationwide survey. *Br J Ophthalmol* 2019;103:338–42.

195 Marmamula S, Furtado JM, Girard L, et al. A cross-sectional study of visual impairment in elderly population in residential care in the South Indian state of Andhra Pradesh: a cross-sectional study. *BMJ Open* 2013;3:e002576.

196 Neena J, Rachel J, Praveen V, et al. Rapid assessment of avoidable blindness in India and Sri Lanka: a cross-sectional study. *BMJ Open* 2018;8:e019040.

197 Nirmalan PK, Thulasiraj RD, Maneksha V, et al. Population based eye survey of older adults in Tirunelveli district of South India: blindness, cataract surgery, and visual outcomes. *Br J Ophthalmol* 2002;86:505–12.

198 Patil S, Gogate P, Vora S, et al. Prevalence, causes of blindness, visual impairment and cataract surgical services in Sindhudurg district on the Western coastal strip of India. *Indian J Ophthalmol* 2014;62:240–5.

199 Vignesh D, Gupta N, Kalaiyan M, et al. Prevalence of visual impairment and its association with vision-related quality of life among elderly persons in a resettlement colony of Delhi. *J Family Med Prim Care* 2019;8:1432.

200 Zhu M, Tong X, Zhao R, et al. Visual impairment and spectacle coverage rate in Baoshan district, China: population-based study. *BMJ Public Health* 2013;13:311.

201 Choi S, Stagg BC, Ehrlich JR. Disparities in Low-Vision device use among older us Medicare recipients. *JAMA Ophthalmal* 2018;136:1399–403.

202 Kuang TM, Tsai S-Y, Hsu W-M, et al. Correctable visual impairment in an elderly Chinese population in Taiwan: the Shihpai eye study. *Invest Ophthalmol Vis Sci* 2007;48:1032–7.

203 Lindsay S, Tsybina I. Predictors of unmet needs for communication and mobility assistive devices among youth with a disability: the role of socio-cultural factors. *Disabil Rehabil Assist Technol* 2011;6:10–21.

204 Eide AH, van Rooy G, Loeb ME. Living conditions among people with activity limitations in Namibia: a representative, national study. Trondheim, Norway, 2003.

205 Eide AH, Ntwariwa S, Madudezi J. Living conditions among people with activity limitations in Zimbabwe. A representative, regional survey, 2003.

206 Eide AH, Neupane S, Hem K-G. Living conditions among people with disability in Nepal, 2016.

207 Eide AH, Munthali A. Living conditions among persons with disabilities in Malawi, a national, representative survey 2017, 2018.

208 JB EAH. Living conditions among people with disabilities in Swaziland a national representative study. Trondheim, Norway, 2011.

209 Eide AH, Kamaleri Y, Hem K-G. Living conditions among people with disabilities in Mozambique: a national representative study, 2009.

210 Eide AH, Mmtal T. Living conditions among people with disability in Botswana. Trondheim, Norway: SINTEF, 2016.

211 Kamaleri Y, Eide AH. Living conditions among people with disabilities in Lesotho. Trondheim, Norway, 2011.

212 Loeb M, Eide AH. Living conditions among people with activity limitations in Malawi: a national representative study. Trondheim, Norway, 2004.

213 Maat S, Jelsma J. Disability and access to health care - a community based descriptive study. *Disabil Rehabil Assist Technol* 2014;9:329–38.

214 Smith N. The face of disability in Nigeria: a disability survey in Kogi and niger states. *CIDC* 2011;22:35–47.

215 Eide A, Sinyengja G, Phiri Mwansa O. 2015 Zambia national disability survey, 2018.

216 Visagie S, Eide AH, Manham H, et al. A description of assistive technology sources, services and outcomes of use in a number of African settings. *Disabil Rehabil Assist Technol* 2017;12:705–12.

217 Loggins S, Alston R, Lewis A. Utilization of assistive technology by persons with physical disabilities: an examination of predictive factors by race. *Disabil Rehabil Assist Technol* 2014;9:487–92.

218 Marella M, Devine A, Armecin GF, et al. Rapid assessment of disability in the Philippines: understanding prevalence, well-being, and access to the community for people with disabilities to inform the W-DARE project. *Popul Health Meas* 2016;14:1–11.

219 Matter RA, Eide AH. Access to assistive technology in two southern African countries. *BMJ Health Serv Res* 2018;18:792.

220 Goins RT, Spencer SM, Goll S, et al. Assistive technology use of older Americans in a southeastern tribe: the native elder care study. *J Am Geriatr Soc* 2010;58:2185–90.

221 Frochen S, Medhizadeh S. Functional status and adaptation: measuring activities of daily living and device use in the National health and aging trends study. *J Aging Health* 2018;30:1136–55.

222 Blos A, Miguel C, Auarin MR, et al. What factors are associated with the provision of assistive technologies: the Bogotá D.C. case. *Disabil Rehabil* 2014;4:932–44.

223 Burton MJ, Ramke J, Marques AP, et al. The Lancet global health Commission on global eye health: vision beyond 2020. *Lancet Glob Health* 2020;12:489–501.

224 World Health Organisation. Prevalence of coverage of assistive technology in the who European region: a scoping review, 2021. Available: http://apps.who.int/bkookorders [Accessed 5 Nov 2021].

225 Holloway C, Austin V, Barbaresco G. Scoping research on assistive technology: on the road for universal assistive technology coverage, 2018. Available: https://at2030.org/static/at2030_core/outputs/Scoping-Report_2019-compressed-192.pdf [Accessed 15 Nov 2021].

226 Rohwedder B. Assistive technologies in developing countries 2018.

227 Mishra S, Pupulin A, Elkan B, et al. National priority assistive product list development in low resource countries: lessons learned from Tajikistan. *Disabil Rehabil Assist Technol*. In Press 2021:16:857–64.

228 Danemayer J, Bhot W, Kular A. At data portal. Available: https://at2030.org/at-data-portal/map/ [Accessed 23 Nov 2021].

229 Danemayer J, Boggs D, Ramos D V. Estimating need and coverage for five priority assistive products. AT2030 programme, 2021. Available: https://at2030.org/estimating-need-and-coverage-for-five-priority-assistive-products/ [Accessed 23 Nov 2021].